---
layout: default
title: Human Immunoglobulin G
description: "Human Immunoglobulin G 的老藥新用潛力分析。中等證據等級 L3，包含 3 個預測適應症。查看 AI 預測與臨床證據完整報告。"
parent: 中證據等級 (L3-L4)
nav_order: 80
evidence_level: L1
indication_count: 3
---

# Human Immunoglobulin G

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
證據等級: <strong>L3</strong> | 預測適應症: <strong>3</strong> 個
</p>

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Human Immunoglobulin G：從免疫調節到糖尿病視網膜病變

## 一句話總結

<p class="key-answer" data-question="Human Immunoglobulin G 可以用於治療什麼新適應症？">
Human immunoglobulin G（IVIG）原本用於免疫不全症、ITP 及川崎氏症等免疫調節治療。
TxGNN 模型預測它可能對**糖尿病視網膜病變 (diabetic retinopathy)** 有效，
目前有 **3 個臨床試驗**和 **20 篇文獻**涉及相關研究。
</p>


## 快速總覽

| 項目 | 內容 |
|------|------|
| 原適應症 | 原發性免疫不全症、ITP、川崎氏症、GBS |
| 預測新適應症 | 糖尿病視網膜病變 (diabetic retinopathy) |
| TxGNN 預測分數 | 99.63% |
| 證據等級 | L3 |
| 台灣上市 | 有效許可證 |
| 許可證數 | 2 張 |
| 建議決策 | Explore |






## 預測適應症詳細分析

<details class="indication-section" open>
<summary>
<span class="indication-name">1. severe nonproliferative diabetic retinopathy</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.75%</span> <span class="primary-badge">主要分析</span>
</summary>
<div class="indication-content">

<h3>為什麼這個預測合理？</h3>

<p>Human immunoglobulin G 是一種免疫調節生物製劑，透過多種機轉發揮作用，</p>
<p>包括中和自體抗體、調節補體系統、影響 Fc 受體功能等。</p>

<p><strong>預測合理性分析：</strong></p>
<ul>
<li>糖尿病視網膜病變涉及慢性發炎和免疫失調</li>
<li>研究顯示 DR 患者血清中 IgG 醣化模式異常，提示 IgG 在疾病中的角色</li>
<li>自體抗體可能參與視網膜周細胞（pericyte）的損傷機轉</li>
<li>補體活化產物（C3a、C5a）在 DR 患者中升高</li>

</ul>
<p><strong>機轉關聯：</strong></p>
<ul>
<li>IgG 醣化改變與 DR 嚴重程度相關（PMID: 33491329, 40204274）</li>
<li>視網膜周細胞反應性自體抗體透過補體介導損傷（PMID: 26839120）</li>
<li>玻璃體液中 IgG 水平在增殖性 DR 中升高（PMID: 32714992）</li>
</ul>

<h3>臨床試驗</h3>

<p>目前無針對此特定適應症的臨床試驗登記。</p>

<h3>相關文獻</h3>

<table>
<thead>
<tr><th>PMID</th><th>年份</th><th>類型</th><th>期刊</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/40204274/" target="_blank">40204274</a></td><td>2025</td><td>Article</td><td>Molecular &amp; cellular proteomic</td><td>Serum Disease-Specific IgG Fc Glycosylation as Potential Biomarkers for Nonproli...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. diabetic retinopathy</span>
<span class="evidence-badge evidence-L1">L1</span>
<span class="prediction-score">99.63%</span>
</summary>
<div class="indication-content">

<h3>臨床試驗（3 項）</h3>

<table>
<thead>
<tr><th>試驗編號</th><th>階段</th><th>狀態</th><th>人數</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01148225" target="_blank">NCT01148225</a></td><td>PHASE3</td><td>COMPLETED</td><td>424</td><td>A Multicenter Open-Label Study of the Long-term Safety and Efficacy of the Human...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02924987" target="_blank">NCT02924987</a></td><td>PHASE4</td><td>UNKNOWN</td><td>40</td><td>Effect of Aflibercept (Eylea®) in the Management of Bevacizumab (Avastin®) Resis...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02443155" target="_blank">NCT02443155</a></td><td>PHASE2</td><td>COMPLETED</td><td>308</td><td>A Randomised, Double-blind, Double-dummy, Placebo-controlled, Parallel-group Mul...</td></tr>
</tbody>
</table>

<h3>相關文獻（20 篇）</h3>

<table>
<thead>
<tr><th>PMID</th><th>年份</th><th>類型</th><th>期刊</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/24311895/" target="_blank">24311895</a></td><td>2013</td><td>Article</td><td>Mediators of inflammation</td><td>Biomarkers in diabetic retinopathy and the therapeutic implications.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/40682148/" target="_blank">40682148</a></td><td>2025</td><td>Article</td><td>Diabetology &amp; metabolic syndro</td><td>Causal association between immunoglobulin G N-glycosylation patterns and diabeti...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/40204274/" target="_blank">40204274</a></td><td>2025</td><td>Article</td><td>Molecular &amp; cellular proteomic</td><td>Serum Disease-Specific IgG Fc Glycosylation as Potential Biomarkers for Nonproli...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/34003908/" target="_blank">34003908</a></td><td>2021</td><td>Article</td><td>Translational vision science &amp;</td><td>Exposure to Porphyromonas gingivalis and Modifiable Risk Factors Modulate Risk f...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/37638581/" target="_blank">37638581</a></td><td>2023</td><td>Article</td><td>Vestnik oftalmologii</td><td>[Faricimab: from research to clinical practice].</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/32714992/" target="_blank">32714992</a></td><td>2020</td><td>Article</td><td>Journal of diabetes research</td><td>Qualitative and Quantitative Analysis of B-Cell-Produced Antibodies in Vitreous ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/2642484/" target="_blank">2642484</a></td><td>1989</td><td>Article</td><td>The Journal of clinical endocr</td><td>Renin, prorenin, and immunoreactive renin in vitreous fluid from eyes with and w...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/33491329/" target="_blank">33491329</a></td><td>2021</td><td>Article</td><td>Journal of diabetes</td><td>Variation of IgG N-linked glycosylation profile in diabetic retinopathy.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/3552537/" target="_blank">3552537</a></td><td>1987</td><td>Article</td><td>Diabetes research and clinical</td><td>Lack of effect of gliclazide on early diabetic nephropathy and retinopathy: a tw...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/2947762/" target="_blank">2947762</a></td><td>1986</td><td>Article</td><td>Clinical and experimental immu</td><td>The relationship of soluble immune complexes, insulin antibodies and insulin-ant...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/10333053/" target="_blank">10333053</a></td><td>1999</td><td>Article</td><td>Diabetologia</td><td>Increased expression of endothelial antigen PAL-E in human diabetic retinopathy ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/2974777/" target="_blank">2974777</a></td><td>1988</td><td>Article</td><td>Diabetic medicine : a journal </td><td>The fluorescence of serum proteins in diabetic patients with and without retinop...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/3924692/" target="_blank">3924692</a></td><td>1985</td><td>Article</td><td>Diabetes</td><td>Urinary excretion of plasma proteins in diabetic subjects. Increased excretion o...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/33625683/" target="_blank">33625683</a></td><td>2021</td><td>Article</td><td>Immunologic research</td><td>Dysregulation of circulating follicular helper T cells in type 2 diabetic patien...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/4900817/" target="_blank">4900817</a></td><td>1969</td><td>Article</td><td>Acta ophthalmologica</td><td>Immunohistological studies on human diabetic and non-diabetic eyes. I. Fluoresce...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/26839120/" target="_blank">26839120</a></td><td>2016</td><td>Article</td><td>Scientific reports</td><td>Presence of retinal pericyte-reactive autoantibodies in diabetic retinopathy pat...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/37364630/" target="_blank">37364630</a></td><td>2023</td><td>Article</td><td>Experimental eye research</td><td>Serum disease-specific IgG Fc glycosylation as potential biomarkers for nonproli...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/2196238/" target="_blank">2196238</a></td><td>1990</td><td>Article</td><td>International ophthalmology</td><td>Immunoglobulin G, complement factor C3 and lymphocytes in proliferative intraocu...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/38987257/" target="_blank">38987257</a></td><td>2024</td><td>Article</td><td>Nutrition &amp; diabetes</td><td>Urine biomarkers in type 2 diabetes mellitus with or without microvascular compl...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/25066224/" target="_blank">25066224</a></td><td>2015</td><td>Article</td><td>Diabetes/metabolism research a</td><td>Higher titers of anti-Chlamydia pneumoniae IgG in diabetic retinopathy: a cross-...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. drug-induced osteoporosis</span>
<span class="evidence-badge evidence-L1">L1</span>
<span class="prediction-score">99.37%</span>
</summary>
<div class="indication-content">

<h3>臨床試驗（2 項）</h3>

<table>
<thead>
<tr><th>試驗編號</th><th>階段</th><th>狀態</th><th>人數</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05493761" target="_blank">NCT05493761</a></td><td>PHASE4</td><td>ACTIVE_NOT_RECRUITING</td><td>72</td><td>Effect of Anti-osteoporotic Medications on Hepatic Steatosis and Fibrosis of Wom...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00559585" target="_blank">NCT00559585</a></td><td>PHASE3</td><td>COMPLETED</td><td>2492</td><td>A Phase IIIB Multicenter, Randomized, Double-Blind, Double-Dummy Study to Compar...</td></tr>
</tbody>
</table>

</div>
</details>


## 台灣上市資訊

| 許可證號 | 品名 | 劑型 | 核准適應症 |
|---------|------|------|-----------|
| 衛署菌疫輸字第000841號 | "國血製劑益康"人類免疫球蛋白靜脈注射劑 | 注射劑 | 原發性免疫不全症、ITP、骨髓移植、川崎氏症、GBS |

## 安全性考量

- **藥物交互作用**：未在 DDI 資料庫中找到重大交互作用
- **注意事項**：
  - 可能引起輸注反應（發燒、寒顫、頭痛）
  - 高劑量 IVIG 有血栓栓塞風險
  - 腎功能不全患者需謹慎使用
- **特殊族群**：糖尿病患者常合併腎病變，使用時需監測腎功能

安全性資訊請參考原廠仿單。

## 結論與下一步

**決策：Explore**

**理由：**
- 多篇文獻支持 IgG 在糖尿病視網膜病變病理機轉中的角色
- 免疫調節在 DR 治療中是尚未被充分探索的方向
- 但目前無直接臨床試驗評估 IVIG 用於 DR 的療效
- IVIG 成本高昂，需進行成本效益評估

**若要推進需要：**
- 基礎研究確認 IVIG 對視網膜周細胞保護作用的機轉
- 小規模臨床試驗評估 IVIG 在 DR 患者中的安全性和初步療效
- 與現有抗 VEGF 治療進行比較或聯合治療研究
- 成本效益分析


---

## 相關藥物報告

- [Aluminum Hydroxide]({{ "/drugs/aluminum_hydroxide/" | relative_url }}) - 證據等級 L3
- [Propantheline]({{ "/drugs/propantheline/" | relative_url }}) - 證據等級 L3
- [Inositol]({{ "/drugs/inositol/" | relative_url }}) - 證據等級 L3
- [Vitamin E]({{ "/drugs/vitamin_e/" | relative_url }}) - 證據等級 L3
- [Alfacalcidol]({{ "/drugs/alfacalcidol/" | relative_url }}) - 證據等級 L3

---

{% include ai-analysis.html %}

{% include social-share.html %}

## 引用本報告

如需引用本報告，請使用以下格式：

**APA 格式：**
```
TwTxGNN. (2026). Human Immunoglobulin G老藥新用驗證報告. https://twtxgnn.yao.care/drugs/human_immunoglobulin_g/
```

**BibTeX 格式：**
```bibtex
@misc{twtxgnn_human_immunoglobulin_g,
  title = {Human Immunoglobulin G老藥新用驗證報告},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/human_immunoglobulin_g/}
}
```

---

<div class="disclaimer">
<strong>免責聲明</strong><br>
本報告僅供學術研究參考，<strong>不構成醫療建議</strong>。藥物使用請遵循醫師指示，切勿自行調整用藥。任何老藥新用決策需經過完整的臨床驗證與法規審查。
<br><br>
<small>最後審核：2026-02-20 | 審核者：TwTxGNN Research Team</small>
</div>

{% include giscus.html %}
